INCY
Incyte Corporation NASDAQ Listed Nov 4, 1993$98.22
-0.78%
vs $98.99
Mkt Cap $19.6B
52w Low $66.74
69.1% of range
52w High $112.29
50d MA $98.17
200d MA $96.80
P/E (TTM)
15.3x
EV/EBITDA
9.2x
P/B
3.7x
Debt/Equity
0.0x
ROE
25.5%
P/FCF
14.6x
RSI (14)
52.10
ATR (14)
$4.33
Beta
0.86
50d MA
$98.17
200d MA
$96.80
Avg Volume
1.8M
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
1801 Augustine Cut-Off · Wilmington, DE 19803 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | 1.38 | 1.81 | +31.2% | 97.74 | +1.5% | +1.4% | -3.9% | +1.7% | +0.2% | +0.1% | — |
| Feb 10, 2026 | TNS | 1.90 | 1.80 | -5.3% | 100.05 | -1.5% | -1.2% | +1.9% | +0.3% | +0.1% | +1.8% | — |
| Oct 28, 2025 | TNS | 1.66 | 2.26 | +36.1% | 91.65 | -0.2% | -1.6% | +2.7% | +1.0% | +8.7% | +1.3% | — |
| Jul 29, 2025 | TNS | 1.39 | 1.57 | +12.9% | 77.38 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% | — |
| Apr 29, 2025 | TNS | 1.01 | 1.16 | +14.9% | 60.43 | +0.9% | +3.7% | -1.0% | +0.8% | -0.7% | -4.0% | — |
| Feb 10, 2025 | TNS | 1.57 | 1.43 | -8.9% | 68.30 | -1.1% | -2.9% | +4.1% | +1.4% | +0.6% | +1.2% | — |
| Oct 29, 2024 | TNS | 1.12 | 1.07 | -4.5% | 73.60 | +0.0% | +0.4% | +0.3% | +2.7% | -0.5% | +2.0% | — |
| Jul 30, 2024 | TNS | 0.78 | -1.82 | -333.3% | 67.79 | +0.1% | -4.0% | -1.0% | +0.1% | -3.8% | -1.2% | — |
| Apr 30, 2024 | TNS | 0.84 | 0.64 | -23.8% | 52.05 | -0.3% | +1.7% | +0.3% | +1.3% | +0.6% | +0.5% | — |
| Feb 13, 2024 | TNS | 1.16 | 1.06 | -8.6% | 59.34 | -1.3% | -2.4% | +1.9% | -1.7% | +1.5% | +2.6% | — |
| Oct 31, 2023 | TNS | 1.09 | 1.10 | +0.9% | 53.93 | +0.1% | +0.8% | -0.7% | +1.6% | -0.5% | +0.3% | — |
| Aug 1, 2023 | TNS | 0.83 | 0.99 | +19.3% | 63.69 | +0.2% | +3.1% | -1.1% | -2.1% | +2.0% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 22 | Bernstein | Initiates | Mkt Perform | $99 | $97.41 | $97.30 | -0.1% | -0.3% | -0.1% | +0.2% | +0.2% | -0.8% |
| Apr 29 | Oppenheimer | Maintains | Perform → Perform | — | $97.74 | $99.18 | +1.5% | +1.4% | -3.9% | +1.7% | +0.2% | +0.3% |
| Apr 29 | Stifel | Maintains | Buy → Buy | — | $97.74 | $99.18 | +1.5% | +1.4% | -3.9% | +1.7% | +0.2% | +0.3% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.69 | $98.75 | +1.1% | -0.6% | -1.8% | +2.6% | -0.9% | -0.7% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.30 | $91.13 | +0.9% | +0.0% | +4.2% | +0.2% | +1.7% | -1.1% |
| Mar 25 | UBS | Maintains | Neutral → Neutral | — | $90.62 | $91.00 | +0.4% | +1.8% | +0.0% | -2.1% | +0.0% | +4.2% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $90.62 | $91.00 | +0.4% | +1.8% | +0.0% | -2.1% | +0.0% | +4.2% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $92.54 | $92.14 | -0.4% | +0.5% | +1.3% | -2.1% | +0.8% | -2.3% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $95.94 | $95.94 | +0.0% | +1.2% | -1.1% | -1.4% | -2.8% | +0.6% |
| Mar 5 | Evercore ISI | Maintains | In Line → In Line | — | $98.86 | $97.99 | -0.9% | -1.5% | -1.4% | +1.2% | -1.1% | -1.4% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $101.16 | $100.77 | -0.4% | +1.8% | -1.2% | -0.4% | -0.5% | +0.2% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $100.05 | $98.52 | -1.5% | -1.2% | +1.9% | +0.3% | +0.1% | +1.8% |
| Feb 11 | Stifel | Maintains | Buy → Buy | — | $100.05 | $98.52 | -1.5% | -1.2% | +1.9% | +0.3% | +0.1% | +1.8% |
| Feb 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $100.05 | $98.52 | -1.5% | -1.2% | +1.9% | +0.3% | +0.1% | +1.8% |
| Feb 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $100.05 | $98.52 | -1.5% | -1.2% | +1.9% | +0.3% | +0.1% | +1.8% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $102.76 | $103.75 | +1.0% | +5.5% | +0.6% | -8.2% | -1.2% | +1.9% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $100.92 | $102.61 | +1.7% | +1.7% | +0.2% | +5.5% | +0.6% | -8.2% |
| Jan 20 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $106.21 | $103.26 | -2.8% | -3.4% | +2.0% | +0.4% | -2.9% | +0.6% |
| Jan 13 | TD Cowen | Maintains | Buy → Buy | — | $106.33 | $106.56 | +0.2% | -2.7% | +2.4% | -0.7% | +0.9% | -3.4% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $101.79 | $101.73 | -0.1% | +4.8% | +3.7% | -4.2% | +0.9% | -0.5% |
| Dec 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $102.52 | $100.13 | -2.3% | -5.7% | -1.6% | +0.0% | +1.0% | -0.7% |
| Dec 8 | Mizuho | Upgrade | Neutral → Outperform | — | $102.52 | $100.13 | -2.3% | -5.7% | -1.6% | +0.0% | +1.0% | -0.7% |
| Dec 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $102.52 | $100.13 | -2.3% | -5.7% | -1.6% | +0.0% | +1.0% | -0.7% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $102.06 | $103.00 | +0.9% | +4.1% | -0.6% | +0.1% | -1.1% | -2.3% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $101.57 | $101.85 | +0.3% | +1.3% | +2.7% | -0.5% | +0.7% | +0.0% |
| Nov 3 | Guggenheim | Upgrade | Neutral → Buy | — | $93.48 | $93.95 | +0.5% | +8.7% | +1.3% | +2.7% | -0.5% | +0.7% |
| Oct 29 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $91.65 | $91.49 | -0.2% | -1.6% | +2.7% | +1.0% | +8.7% | +1.3% |
| Oct 29 | Truist | Maintains | Hold → Hold | — | $91.65 | $91.49 | -0.2% | -1.6% | +2.7% | +1.0% | +8.7% | +1.3% |
| Oct 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $91.65 | $91.49 | -0.2% | -1.6% | +2.7% | +1.0% | +8.7% | +1.3% |
| Oct 29 | Barclays | Maintains | Overweight → Overweight | — | $91.65 | $91.49 | -0.2% | -1.6% | +2.7% | +1.0% | +8.7% | +1.3% |
| Oct 9 | JP Morgan | Maintains | Neutral → Neutral | — | $85.38 | $85.55 | +0.2% | -0.7% | -1.1% | +1.1% | +1.5% | +2.5% |
| Sep 24 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $84.54 | $84.19 | -0.4% | -0.4% | -3.0% | +1.3% | +1.4% | +1.1% |
| Sep 22 | Stifel | Maintains | Buy → Buy | — | $86.53 | $86.39 | -0.2% | -2.1% | -0.2% | -0.4% | -3.0% | +1.3% |
| Sep 19 | Guggenheim | Maintains | Neutral → Neutral | — | $86.00 | $85.86 | -0.2% | +0.6% | -2.1% | -0.2% | -0.4% | -3.0% |
| Sep 4 | BofA Securities | Maintains | Buy → Buy | — | $86.96 | $87.26 | +0.3% | -1.7% | +1.4% | -0.1% | -1.1% | +0.8% |
| Aug 22 | JP Morgan | Maintains | Neutral → Neutral | — | $86.53 | $87.00 | +0.5% | -1.7% | -0.3% | -0.9% | +1.0% | -1.3% |
| Aug 6 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $77.72 | $78.62 | +1.2% | -0.1% | +0.7% | +0.2% | +1.0% | +3.1% |
| Jul 30 | UBS | Maintains | Neutral → Neutral | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 30 | BMO Capital | Maintains | Underperform → Underperform | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 30 | Citigroup | Maintains | Buy → Buy | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 30 | Truist | Maintains | Hold → Hold | — | $77.38 | $77.84 | +0.6% | +0.2% | -3.4% | +0.9% | +3.2% | -0.4% |
| Jul 14 | JP Morgan | Maintains | Neutral → Neutral | — | $68.59 | $68.77 | +0.3% | +2.0% | -2.5% | +1.4% | -0.4% | -1.6% |
| Jun 16 | Stifel | Upgrade | Hold → Buy | — | $67.75 | $70.80 | +4.5% | +5.1% | -3.4% | -0.8% | +0.3% | -1.8% |
| Jun 3 | UBS | Maintains | Neutral → Neutral | — | $65.31 | $65.12 | -0.3% | +2.8% | +0.5% | -0.3% | +2.3% | +1.6% |
| May 27 | Truist | Maintains | Hold → Hold | — | $64.25 | $64.95 | +1.1% | +1.7% | -0.6% | +1.7% | -1.5% | +0.4% |
| Apr 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $60.43 | $60.95 | +0.9% | +3.7% | -1.0% | +0.8% | -0.7% | -4.0% |
| Apr 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $60.43 | $60.95 | +0.9% | +3.7% | -1.0% | +0.8% | -0.7% | -4.0% |
| Apr 21 | JP Morgan | Maintains | Neutral → Neutral | — | $58.21 | $57.48 | -1.3% | -2.4% | +1.0% | +1.1% | +1.7% | +0.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Tray ThomasOff | Principal Accounting Officer | Sell | 2,639 | $100.00 | $264K | 21,132 | +2.57% | -6.04% |
| May 26, 2026 | Tray ThomasOff | Principal Accounting Officer | Sell | 2,051 | $97.35 | $200K | 21,132 | -0.78% | +3.33% |
| May 19, 2026 | Clancy Paul JDir | — | Sell | 15,000 | $94.93 | $1.4M | 23,741 | -0.26% | -0.78% |
8-K · 8.01
!! High
Incyte Corporation -- 8-K 8.01: Material Event / Announcement
Jun 8
8-K · 1.01
!! High
MacroGenics, Inc. -- 8-K 1.01: License Agreement
MacroGenics licensed technology to Sage Therapeutics for $60 million upfront, providing near-term revenue while validating its platform and potentially generating future royalties.
May 4
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte delivered strong Q1 2026 results with 20% year-over-year net sales growth, demonstrating solid commercial execution and providing positive momentum heading into the remainder of the year.
Apr 28
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive departure signals potential strategic uncertainty, which could concern investors if the departing executive held critical operational or R&D responsibilities affecting pipeline progress or earnings guidance.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Incyte's executive leadership restructuring signals management confidence in executing strategy, though investors should monitor whether these appointments strengthen drug development pipelines or indicate preparation for operational challenges ahead.
Mar 26
8-K · 8.01
!! High
Incyte Genomics Inc -- 8-K 8.01: Material Event / Announcement
Incyte received an FDA Complete Response Letter for Zynyz in lung cancer, delaying the supplemental approval despite positive Phase 3 trial data, requiring additional information before resubmission.
Mar 6
8-K
Incyte Genomics Inc -- 8-K Filing
Incyte reported strong fourth quarter and full-year 2025 results driven by core business growth and pipeline advancement, while providing 2026 financial guidance to investors.
Feb 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dodge & Cox | 12,252,356 | $1.2B | Reduced | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 10,930,066 | $1.0B | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 7,759,183 | $730M | New | Mar 2026 |
| 4 | Aqr Capital Management Llc | 5,807,930 | $536M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 5,327,646 | $526M | Added | Dec 2025 |
| 6 | Invesco Ltd. | 3,870,764 | $364M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 3,651,532 | $344M | Reduced | Mar 2026 |
| 8 | Arrowstreet Capital, Limited Partnership | 2,830,799 | $266M | Reduced | Mar 2026 |
| 9 | Robeco Institutional Asset Management B.v. | 2,514,383 | $237M | Added | Mar 2026 |
| 10 | Los Angeles Capital Management Llc | 2,144,847 | $202M | Reduced | Mar 2026 |
| 11 | Acadian Asset Management Llc | 1,900,824 | $179M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 1,849,726 | $174M | Added | Mar 2026 |
| 13 | Victory Capital Management Inc | 1,742,870 | $164M | Added | Mar 2026 |
| 14 | First Trust Advisors Lp | 1,500,792 | $141M | Added | Mar 2026 |
| 15 | Pictet Asset Management Holding Sa | 1,315,666 | $130M | Added | Dec 2025 |
| 16 | Marshall Wace, Llp | 1,253,138 | $118M | Added | Mar 2026 |
| 17 | Panagora Asset Management Inc | 1,210,909 | $114M | Added | Mar 2026 |
| 18 | Fmr Llc | 1,172,890 | $110M | Reduced | Mar 2026 |
| 19 | Ubs Group Ag | 1,138,004 | $107M | Added | Mar 2026 |
| 20 | Royal Bank Of Canada | 1,054,123 | $99M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$19.62B
Enterprise Value
$16.15B
P/E (TTM)
15.32x
Forward P/E
13.12x
PEG Ratio
0.00x
P/B
3.72x
P/S
3.83x
P/FCF
14.55x
EV/EBITDA
9.17x
Shares Out
200.7M
Financials (TTM)
Revenue
$5.14B
Net Income
$1.29B
EBITDA
$1.76B
Free Cash Flow
$1.35B
Op Cash Flow
$1.41B
EPS Basic
$6.59
EPS Diluted
$6.41
EPS Forward
$7.48
Gross Margin
91.5%
Op Margin
26.1%
Net Margin
25.0%
Balance Sheet
Total Assets
$6.96B
Total Liab.
$1.80B
Total Equity
$5.17B
Cash
$3.58B
LT Debt
$14.5M
Book Value/Sh
$26.41
Debt/Equity
0.01x
Current Ratio
3.32
Quick Ratio
3.25
Returns & Growth
ROE
25.5%
ROA
19.5%
ROIC
20.6%
Rev Growth YoY
+21.2%
EPS Growth YoY
+4018.8%
Price Returns
2W
-0.9%
1M
+1.5%
3M
-4.5%
6M
-7.4%
12M
+48.7%
Technicals
52W High
$112.29
52W Low
$66.74
50d MA
$98.17
200d MA
$96.80
RSI (14)
52.10
ATR (14)
$4.33
Beta
0.86
Avg Volume
1.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$109.50
High
$135.00
Low
$90.00
Median
$108.50
Data updated apr 25, 2026 3:30pm
· Source: financialmodelingprep.com